Monday, October 19, 2015
The Parkinson’s Disease Foundation (PDF) and the American Parkinson Disease Association (APDA) are collaborating on Summer Student Fellowships to support research that will help solve, treat and end Parkinson’s disease. The collaboration expands opportunities for undergraduates and medical students to gain early exposure to careers in Parkinson’s by conducting 10-week research fellowships with established leaders in the field. The collaboration reflects PDF and APDA’s shared commitment to cultivating students’ early interest and leadership in Parkinson’s research.
Parkinson’s U.K., one of the world’s largest charity funders of Parkinson’s research, and Critical Path Institute (C-Path), an Arizona-based nonprofit organization dedicated to accelerating the pace and reducing the costs of medical product development, have formed the Critical Path for Parkinson’s Consortium (CPP).
GTx, a Memphis-based biopharmaceutical company, has announced that the FDA has accepted the company’s investigational new drug (IND) application for a phase II clinical trial to treat postmenopausal women with stress urinary incontinence (SUI). The IND enables GTx to initiate a phase II proof-of-concept trial of enobosarm that will be the first clinical trial to evaluate a selective androgen receptor modulator (SARM) for SUI. The company plans to initiate the trial by the first quarter of 2016 and anticipates top-line data later in 2016.
Cambridge, Mass.-based Ironwood Pharmaceuticals has announced that the phase III clinical trial of its 72mcg dose of linaclotide in adults with chronic idiopathic constipation (CIC) met the primary endpoint. Ironwood and partner Allergan intend to submit a supplemental new drug application to the FDA in the first half of 2016.
Researchers funded by the NIH and the Foundation for the NIH (FNIH) have expanded a recently launched online library, called a knowledge portal, which allows open-access searching of human genetic and clinical information on type 2 diabetes. Individual data will remain confidential. The portal includes information from several major international networks, collected from decades of research.
Cancer Genetics, a DNA-based cancer diagnostics provider, has received approval from the U.S. bankruptcy court in Delaware to purchase substantially all of the assets of Los Angeles-based Response Genetics Inc. (RGI), a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. CGI also agreed to assume some of RGI’s liabilities. The sale is subject to certain customary closing conditions and is expected to close by Oct. 9.